600572 康恩贝
已收盘 02-04 15:00:00
资讯
新帖
简况
康恩贝(600572.SH)子公司TFA003片获得药物临床试验批准通知书
智通财经 · 17:17
康恩贝(600572.SH)子公司TFA003片获得药物临床试验批准通知书
康恩贝（600572）披露2026年度日常关联交易预计议案，2月2日股价下跌0.67%
证券之星 · 02-02 22:38
康恩贝（600572）披露2026年度日常关联交易预计议案，2月2日股价下跌0.67%
每周股票复盘：胡季强减持康恩贝（600572）0.763%股份
证券之星 · 02-01
每周股票复盘：胡季强减持康恩贝（600572）0.763%股份
康恩贝（600572）披露股东集中竞价减持股份计划公告，1月29日股价下跌0.22%
证券之星 · 01-29
康恩贝（600572）披露股东集中竞价减持股份计划公告，1月29日股价下跌0.22%
1月26日康恩贝发布公告，股东减持1933.55万股
证券之星 · 01-26
1月26日康恩贝发布公告，股东减持1933.55万股
每周股票复盘：康恩贝（600572）预计2026年日常关联交易不超11.71亿元
证券之星 · 01-25
每周股票复盘：康恩贝（600572）预计2026年日常关联交易不超11.71亿元
康恩贝（600572）披露召开2026年第一次临时股东会的通知，1月23日股价上涨0.66%
证券之星 · 01-23
康恩贝（600572）披露召开2026年第一次临时股东会的通知，1月23日股价上涨0.66%
每周股票复盘：康恩贝（600572）大股东减持1.998%股份
证券之星 · 01-18
每周股票复盘：康恩贝（600572）大股东减持1.998%股份
康恩贝（600572）发布关于控股股东浙药集团增持股份结果暨权益变动触及1%刻度的公告，1月16日股价下跌0.44%
证券之星 · 01-16
康恩贝（600572）发布关于控股股东浙药集团增持股份结果暨权益变动触及1%刻度的公告，1月16日股价下跌0.44%
1月16日康恩贝现2.15亿元大宗交易
证券之星 · 01-16
1月16日康恩贝现2.15亿元大宗交易
康恩贝（600572）披露修订《公司章程》及变更法定代表人完成工商变更登记，1月13日股价上涨0.22%
证券之星 · 01-13
康恩贝（600572）披露修订《公司章程》及变更法定代表人完成工商变更登记，1月13日股价上涨0.22%
每周股票复盘：康恩贝（600572）Q4行权新增963.857万股
证券之星 · 01-11
每周股票复盘：康恩贝（600572）Q4行权新增963.857万股
康恩贝（600572）披露2025年第四季度股票期权激励计划自主行权结果暨股份变动公告，1月5日股价上涨0.67%
证券之星 · 01-05
康恩贝（600572）披露2025年第四季度股票期权激励计划自主行权结果暨股份变动公告，1月5日股价上涨0.67%
每周股票复盘：康恩贝（600572）子公司获药品注册证书
证券之星 · 01-02
每周股票复盘：康恩贝（600572）子公司获药品注册证书
康恩贝最新公告：选举应徐颉任董事长
证券之星 · 2025-12-30
康恩贝最新公告：选举应徐颉任董事长
每周股票复盘：康恩贝（600572）股东会增补两名董事
证券之星 · 2025-12-28
每周股票复盘：康恩贝（600572）股东会增补两名董事
A股公告精选 | 康恩贝(600572.SH)拟转让2%公司股份
智通财经网 · 2025-12-22
A股公告精选 | 康恩贝(600572.SH)拟转让2%公司股份
康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份
美股速递 · 2025-12-22
康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份
康恩贝(600572.SH)控股股东拟增持1.999%公司股份
智通财经 · 2025-12-22
康恩贝(600572.SH)控股股东拟增持1.999%公司股份
康恩贝董事长“闪离”背后：频繁人事震荡与增长乏力下的治理隐忧
新浪证券 · 2025-12-12
康恩贝董事长“闪离”背后：频繁人事震荡与增长乏力下的治理隐忧
加载更多
公司概况
公司名称：
浙江康恩贝制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-04-12
主营业务：
浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。
发行价格：
8.25
{"stockData":{"symbol":"600572","market":"SH","secType":"STK","nameCN":"康恩贝","latestPrice":4.5,"timestamp":1770188401000,"preClose":4.48,"halted":0,"volume":40618589,"delay":0,"changeRate":0.0045,"floatShares":2529000000,"shares":2536000000,"eps":0.2713,"marketStatus":"已收盘","change":0.02,"latestTime":"02-04 15:00:00","open":4.47,"high":4.51,"low":4.45,"amount":182000000,"amplitude":0.0134,"askPrice":4.51,"askSize":31363,"bidPrice":4.5,"bidSize":12923,"shortable":0,"etf":0,"ttmEps":0.2713,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":5,"adr":0,"adjPreClose":4.48,"symbolType":"stock","openAndCloseTimeList":[[1770168600000,1770175800000],[1770181200000,1770188400000]],"highLimit":4.93,"lowLimit":4.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2535961241,"isCdr":false,"pbRate":1.62,"roa":"--","peRate":16.586804,"roe":"8.05%","epsLYR":0.25,"committee":-0.206098,"marketValue":11412000000,"turnoverRate":0.0161,"status":0,"floatMarketCap":11381000000},"requestUrl":"/m/hq/s/600572","defaultTab":"news","newsList":[{"id":"2608351739","title":"康恩贝(600572.SH)子公司TFA003片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351739?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:17","pubTimestamp":1770196622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康恩贝(600572.SH)发布公告，近日，公司全资子公司杭州康恩贝制药有限公司(简称“杭州康恩贝”)收到国家药品监督管理局核准签发的TFA003片的《药物临床试验批准通知书》。审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年10月16日受理的TFA003片符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意本品开展用于糖尿病肾脏疾病的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0239","600572","BK0012","BK0060","BK0188","BK0028"],"gpt_icon":0},{"id":"2608018867","title":"康恩贝（600572）披露2026年度日常关联交易预计议案，2月2日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608018867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608018867?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:38","pubTimestamp":1770043103,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，康恩贝报收于4.48元，较前一交易日下跌0.67%，最新总市值为113.61亿元。近日，浙江康恩贝制药股份有限公司披露《康恩贝2026年第一次临时股东会会议材料》，拟提交《关于公司2026年度日常关联交易预计的议案》。公告显示，公司预计2026年与英特集团、康恩贝集团及珍视明公司发生日常关联交易总额不超过117,131万元。该事项需提交股东大会审议，关联股东需回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0097","BK0028","BK0239","600572","BK0188","BK0012"],"gpt_icon":0},{"id":"2608072738","title":"每周股票复盘：胡季强减持康恩贝（600572）0.763%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072738","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072738?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:56","pubTimestamp":1769882172,"startTime":"0","endTime":"0","summary":"本次权益变动后，胡季强及其一致行动人康恩贝集团合计持股比例由10.480%下降至9.717%，权益变动比例触及1%刻度。胡季强先生与康恩贝集团合计持有公司股份242,529,556股，占总股本9.564%，累计质押股份占合计持股的17.804%，占公司总股本1.703%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000414.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0060","BK0028","600572","BK0188","BK0239","BK0012"],"gpt_icon":0},{"id":"2607036706","title":"康恩贝（600572）披露股东集中竞价减持股份计划公告，1月29日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036706","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607036706?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:07","pubTimestamp":1769699234,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，康恩贝报收于4.57元，较前一交易日下跌0.22%，最新总市值为115.85亿元。近日，康恩贝发布《关于公司股东集中竞价减持股份计划的公告》。公告显示，康恩贝集团有限公司现持有浙江康恩贝制药股份有限公司178,529,551股，占总股本的7.040%。康恩贝集团因发展自身业务的资金需求，拟自公告披露之日起15个交易日后的3个月内，通过集中竞价交易方式减持不超过25,359,600股，减持比例不超过公司总股本的1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0012","600572","BK0028","BK0239","BK0097"],"gpt_icon":0},{"id":"2606194282","title":"1月26日康恩贝发布公告，股东减持1933.55万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606194282","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606194282?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:33","pubTimestamp":1769423617,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日康恩贝发布公告《康恩贝:关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东胡季强于2026年1月20日至2026年1月26日间合计减持1933.55万股，占公司目前总股本的0.7627%，变动期间该股股价上涨3.76%，截止1月26日收盘报4.69元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0060","BK0028","600572","BK0188","BK0239","BK0012"],"gpt_icon":0},{"id":"2606234096","title":"每周股票复盘：康恩贝（600572）预计2026年日常关联交易不超11.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234096?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:04","pubTimestamp":1769277853,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：康恩贝预计2026年日常关联交易总额不超过117,131万元。公司公告汇总：康恩贝将于2026年2月9日召开临时股东会审议关联交易事项。2026年度日常关联交易中，与英特集团预计交易额不超过101,200万元，主要用于医药产品销售；与康恩贝集团预计交易额15,331万元，涉及采购化学原料等；与珍视明公司预计交易额600万元，用于危废处置等业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0097","600572","BK0188","BK0012","BK0239","BK0028"],"gpt_icon":0},{"id":"2605406880","title":"康恩贝（600572）披露召开2026年第一次临时股东会的通知，1月23日股价上涨0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605406880","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605406880?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:29","pubTimestamp":1769178550,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，康恩贝报收于4.6元，较前一交易日上涨0.66%，最新总市值为116.61亿元。近日，康恩贝发布《关于召开2026年第一次临时股东会的通知》。公告显示，公司将于2026年2月9日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合方式，股权登记日为2026年2月2日。会议审议《关于公司2026年度日常关联交易预计的议案》，包括与英特集团、康恩贝集团、珍视明公司之间的日常关联交易金额预计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","600572","BK0239","BK0028","BK0012","BK0060"],"gpt_icon":0},{"id":"2604925394","title":"每周股票复盘：康恩贝（600572）大股东减持1.998%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925394","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925394?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:43","pubTimestamp":1768678987,"startTime":"0","endTime":"0","summary":"本周关注点来自交易信息汇总：1月16日康恩贝发生2.15亿元大宗交易 来自股本股东变化：康恩贝集团减持1.998%股份，持股比例降至7.043% 来自公司公告汇总：浙药集团增持1.998%股份，持股升至25.438% 交易信息汇总1月16日康恩贝发生一笔2.15亿元的大宗交易。股本股东变化第二大股东康恩贝集团于2026年1月16日通过大宗交易减持50,659,020股，占总股本1.998%，持股比例由9.044%降至7.043%。控股股东浙药集团受让上述股份，持股比例由23.449%升至25.438%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600572","BK0188","BK0097","BK0012","BK0028","BK0060"],"gpt_icon":0},{"id":"2603994485","title":"康恩贝（600572）发布关于控股股东浙药集团增持股份结果暨权益变动触及1%刻度的公告，1月16日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603994485","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603994485?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:41","pubTimestamp":1768574470,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，康恩贝报收于4.5元，较前一交易日下跌0.44%，最新总市值为114.06亿元。该股当日开盘4.53元，最高4.54元，最低4.47元，成交额达1.3亿元，换手率为1.14%。近日，浙江康恩贝制药股份有限公司发布公告称，公司于2026年1月16日收到控股股东浙江省医药健康产业集团有限公司通知，浙药集团通过大宗交易方式完成增持公司股份50,659,020股，占总股本1.998%，增持金额215,300,835元。本次增持后，浙药集团持股比例由23.449%上升至25.438%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","600572","BK0012","BK0097","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2603296143","title":"1月16日康恩贝现2.15亿元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2603296143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603296143?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:35","pubTimestamp":1768556144,"startTime":"0","endTime":"0","summary":"证券之星消息，1月16日康恩贝发生大宗交易，交易数据如下：大宗交易成交价格4.25元，相对当日收盘价折价5.56%，成交5065.9万股，成交金额21530.1万元，买方营业部为国投证券股份有限公司上海虹口区杨树浦路证券营业部，卖方营业部为中信证券股份有限公司杭州庆春路证券营业部。近三个月该股共发生1笔大宗交易，合计成交50.66万手，折价成交1笔。截至2026年1月16日收盘，康恩贝报收于4.5元，下跌0.44%，换手率1.14%，成交量28.93万手，成交额1.3亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600028890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0097","600572","BK0060","BK0239","BK0012"],"gpt_icon":0},{"id":"2603680165","title":"康恩贝（600572）披露修订《公司章程》及变更法定代表人完成工商变更登记，1月13日股价上涨0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680165?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:18","pubTimestamp":1768313903,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，康恩贝报收于4.54元，较前一交易日上涨0.22%，最新总市值为115.07亿元。公司近日发布公告称，浙江康恩贝制药股份有限公司已完成《公司章程》修订及法定代表人变更的工商登记，并取得新的营业执照。公司因注销回购股份63,579,048股，总股本由2,570,037,319股变更为2,506,458,271股，注册资本相应变更。2025年12月30日，应徐颉当选公司第十一届董事会董事长，并担任法定代表人。公司已履行减资公告程序，未收到债权人清偿或担保要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600572","BK0097","BK0239","BK0060","BK0028","BK0188"],"gpt_icon":0},{"id":"2602364925","title":"每周股票复盘：康恩贝（600572）Q4行权新增963.857万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602364925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602364925?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:09","pubTimestamp":1768075749,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，康恩贝报收于4.52元，较上周的4.46元上涨1.35%。本周，康恩贝1月7日盘中最高价报4.52元。康恩贝当前最新总市值114.56亿元，在中药板块市值排名20/67，在两市A股市值排名1793/5182。公司公告汇总浙江康恩贝制药股份有限公司2025年第四季度，2022年股票期权激励计划激励对象行权且完成股份过户登记的股票数量合计为963.8570万股，募集资金3,498.80万元，全部用于补充流动资金。本次行权新增股份为无限售条件流通股，股本总额增加至2,534,568,941股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","600572","BK0239","BK0012","BK0188","BK0097"],"gpt_icon":0},{"id":"2601887005","title":"康恩贝（600572）披露2025年第四季度股票期权激励计划自主行权结果暨股份变动公告，1月5日股价上涨0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601887005?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:39","pubTimestamp":1767623959,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，康恩贝报收于4.49元，较前一交易日上涨0.67%，最新总市值为113.8亿元。近日，康恩贝发布《关于2025年第四季度股票期权激励计划自主行权结果暨股份变动公告》。公告显示，2025年第四季度，公司2022年股票期权激励计划的激励对象行权且完成股份过户登记的股票数量合计为963.8570万股，募集资金3,498.80万元，全部用于补充流动资金。本次行权新增股份为无限售条件流通股，股本总额增加至2,534,568,941股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","BK0012","600572","BK0028","BK0239","BK0097"],"gpt_icon":0},{"id":"2600770035","title":"每周股票复盘：康恩贝（600572）子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2600770035","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600770035?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:15","pubTimestamp":1767291312,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，康恩贝报收于4.51元，较上周的4.66元下跌3.22%。本周关注点公司公告汇总：子公司盐酸丙卡特罗吸入溶液获药品注册证书，视同通过仿制药一致性评价。截至目前，金华康恩贝对该产品累计研发投入约685万元。徐春玲女士持有公司股份50,000股，不存在未履行完毕的公开承诺，将继续遵守相关减持规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0097","BK0239","BK0188","BK0028","BK0012","BK0060"],"gpt_icon":0},{"id":"2595935617","title":"康恩贝最新公告：选举应徐颉任董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2595935617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595935617?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:32","pubTimestamp":1767087172,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，12月30日，公司召开第十一届董事会第十四次（临时）会议，审议通过《关于选举公司董事长、副董事长的议案》《关于选举代表公司执行公司事务董事的议案》等议案。全体董事一致同意选举应徐颉任公司第十一届董事会董事长、金军丽任公司第十一届董事会副董事长；同意选举应徐颉为代表公司执行公司事务的董事，并担任公司法定代表人。以上人员任期均自本次董事会审议通过之日起至第十一届董事会任期届满之日止。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000029145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0239","BK0188","BK0097","BK0012","600572"],"gpt_icon":0},{"id":"2594424522","title":"每周股票复盘：康恩贝（600572）股东会增补两名董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594424522","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594424522?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:09","pubTimestamp":1766866150,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，康恩贝报收于4.51元，较上周的4.66元下跌3.22%。股本股东变化：第二大股东康恩贝集团拟通过大宗交易减持不超过2%股份，控股股东浙药集团将受让该股份。公司公告汇总浙江康恩贝制药股份有限公司于2025年12月22日召开2025年第二次临时股东会，审议通过增补应徐颉、金军丽为公司第十一届董事会非独立董事的议案。本次减持的受让方为公司控股股东浙江省医药健康产业集团有限公司，减持不会导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0012","600572","BK0239","BK0028","BK0188","BK0060"],"gpt_icon":0},{"id":"2593482905","title":"A股公告精选 | 康恩贝(600572.SH)拟转让2%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482905","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593482905?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:59","pubTimestamp":1766404770,"startTime":"0","endTime":"0","summary":"康恩贝：第二大股东康恩贝集团以大宗交易方式向控股股东转让2%公司股份","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251222/20251222200019_89638.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251222/20251222200019_89638.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0012","BK0060","159982","399300","BK0028","BK0188","600572","BK0097"],"gpt_icon":0},{"id":"1108162412","title":"康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1108162412","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108162412?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:37","pubTimestamp":1766399853,"startTime":"0","endTime":"0","summary":"康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","600572","BK0012","BK0097","BK0188","BK0060"],"gpt_icon":0},{"id":"2593486285","title":"康恩贝(600572.SH)控股股东拟增持1.999%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593486285","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593486285?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:21","pubTimestamp":1766398869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康恩贝(600572.SH)发布公告，基于对公司发展前景的坚定信心、对公司长期投资价值的认可，以及进一步提升控制力的需要，公司控股股东浙药集团计划于自公告披露之日后15个交易日后的3个月内通过上海证券交易所以大宗交易的方式增持公司股份，拟增持股数为5065.9万股，占公司现总股本的1.999%。公司第二大股东康恩贝集团有限公司(简称“康恩贝集团”)为本次浙药集团增持股份的大宗交易转让方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康恩贝(600572.SH)控股股东拟增持1.999%公司股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0028","BK0097","BK0012","BK0188","600572","BK0239"],"gpt_icon":0},{"id":"2590263579","title":"康恩贝董事长“闪离”背后：频繁人事震荡与增长乏力下的治理隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2590263579","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590263579?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:24","pubTimestamp":1765527840,"startTime":"0","endTime":"0","summary":"12月5日，浙江康恩贝制药股份有限公司一纸公告，宣布董事长、法定代表人姜毅因“工作调整”辞去所有职务，其董事会任期原应至2027年。自2024年8月正式掌舵至离任，其任职时间不足一年半。一同辞任的还有一位董事。在业绩承压、股价长期低迷的背景下，这一高频人事变动迅速引发市场对其内部治理与战略连续性的深切担忧。康恩贝当前的回应，显然未能有效安抚市场。 人事震荡之外，康恩贝的基本面同样凸显隐忧。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-12/doc-inhaprxi5673564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0097","BK0012","BK0028","BK0060","600572","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770216906051,"stockEarnings":[{"period":"1week","weight":-0.0282},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0608},{"period":"6month","weight":-0.0197},{"period":"1year","weight":0.02},{"period":"ytd","weight":0.0045}],"compareEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":0.0249},{"period":"3month","weight":0.0248},{"period":"6month","weight":0.1176},{"period":"1year","weight":0.2514},{"period":"ytd","weight":0.0249}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江康恩贝制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81016人(较上一季度增加0.59%)","perCapita":"31218股","listingDate":"2004-04-12","address":"浙江省金华市兰溪市康恩贝大道1号","registeredCapital":"253596万元","survey":" 浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。","listedPrice":8.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康恩贝,600572,康恩贝股票,康恩贝股票老虎,康恩贝股票老虎国际,康恩贝行情,康恩贝股票行情,康恩贝股价,康恩贝股市,康恩贝股票价格,康恩贝股票交易,康恩贝股票购买,康恩贝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}